[Abstract] Clinical guidelines recommend trastuzumab as one of the standard adjuvant treatments for early?stage HER2?positive breast cancer. Researchers are continuing to look for new potential breakthroughs based on the previous studies:on one hand, scientists try to reduce the recurrence rate for early?stage HER2?positive breast cancer by adding a second HER2?targeted treatment or extending therapy duration, on the other hand, other researchers attempt to reduce side?effects of unnecessary medical treatment by cutting the dosage of chemotherapy or using shorter course chemotherapy. In this review, we summarize some large clinical study results in recent years and focus on those following topics:1. Is anti?HER2 targeted therapy required for patients with HER2?Low expression breast cancer?2. Can we use short?course anti?HER2 therapy? 3. Will it improve clinical outcome by using two HER2 Blocker together for the treatment of early?stage HER2?positive breast cancer? 4. Will it be able to reduce chemotherapy? This review will provide new insight and recommendations for oncologists and clinicians on HER2?targeted therapy for early?stage HER2?positive breast cancer.